AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

C4 Therapeutics, Inc. Director's Dealing 2020

Oct 2, 2020

33861_dirs_2020-10-01_5de49cab-a100-481f-b037-f1f6e388a84c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2020-10-01

Reporting Person: Siegel Jolie (Chief Legal Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$4.98	2030-07-02	Common Stock (296321)		Direct

Footnotes

F1: 20% of this option shall vest and become exercisable on July 1, 2021, with the remainder vesting in 16 equal quarterly installments thereafter.